MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
This article was originally published in The Gray Sheet
Executive Summary
Preliminary results of Boston Scientific's MADIT-CRT study show a significant benefit for cardiac resynchronization therapy implants over conventional defibrillators for patients with mild heart failure; the data could support expanded labeling and increased market adoption for the premium-priced devices, industry watchers say